Semaglutide Once weekly semaglutide was evaluated in the STEP-1, phase 3, double-blind placebo-controlled study, which enrolled 1,961 adults with a BMI of 30 or greater ( 27 in persons with 1 weight-related coexisting condition), who did not have diabetes
This non-invasive treatment reduces inflammation, improves circulation, and accelerates tissue repair without causing discomfort
In study after study, BPC-157 has shown the ability to tame inflammation when it gets out of control
This peptides inflammation-fighting properties are well-recorded
HSS Journal: The Musculoskeletal Journal of Hospital for Special Surgery , 21(3), 115